Mobosertinib (Evantuzumab) versus evantumumab in injectable or oral form

Mobocertinib is an oral small molecule targeted drug mainly used to treat patients with non-small cell lung cancer (NSCLC) carrying EGFR exon 20 insertion mutations. It inhibits tumor cell proliferation and survival by reversibly inhibiting mutant EGFR kinase activity and blocking downstream signaling pathways. In contrast, Amivantamab is a bispecific monoclonal antibody that is administered via intravenous injection and can target both EGFR and MET receptors to exert antibody-dependent cytotoxicity on mutant tumor cells.

Mobosetinib is taken in the form of oral tablets, which facilitates patients to complete treatment in a home environment, improves medication compliance, and facilitates long-term maintenance of treatment. Oral administration allows physicians the flexibility to adjust dosage based on patient tolerance. Evantumumab needs to be administered by intravenous infusion, usually in a hospital or specialized medical facility. Each infusion takes a certain amount of time and needs to be monitored by a medical team to prevent infusion-related reactions.

Oral moboxetinib is suitable for patients who require long-term maintenance treatment or have limited mobility. Its use is more convenient, but patients need to strictly abide by the medication time and dosage to ensure efficacy and safety. Although injectable evantumumab is not as convenient as oral drugs in terms of administration convenience, due to its antibody properties, its blood concentration is relatively stable, and it can enhance the immune system's killing effect on tumors through antibody-dependent cytotoxicity, which may provide a more comprehensive therapeutic effect for some patients.
In terms of clinical selection, doctors will decide on a drug plan based on the patient's mutation type, treatment history, physical condition and medication compliance. For patients who are able to self-administer oral medications, moboxetinib can provide convenient and continuous targeted therapy; for patients who need rapid blood concentration control or hope to enhance the therapeutic effect through antibody mechanisms, evantumumab injection is a more suitable choice. At the same time, the efficacy and side effects need to be closely monitored during treatment to ensure safety and effectiveness.
Reference link: https://www.drugs.com